Merck recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant ...

Cheng Xin / Getty Images Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce ...

Merck Manuals is launching a new artificial intelligence-powered search tool designed to provide patients with streamlined access to trusted information and resources from its medical manuals.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

Merck & Co., Inc. (NYSE:MRK) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Cantor Fitzgerald reaffirmed its Neutral rating on Merck & Co., Inc. (NYSE:MRK) with a fixed ...

June 2 (Reuters) - Merck (MRK.N), opens new tab has held talks to buy Swiss biotech MoonLake Immunotherapeutics (MLTX.O), opens new tab for more than $3 billion, the Financial Times reported on ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could be a steal of a deal.(Seth Wenig / AP) Shares of pharmaceutical ...

June 9 (Reuters) - Merck's (MRK.N), opens new tab oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers ...

Merck made a nonbinding offer of over $3 billion for MoonLake, whose lead drug is in Phase 3 trials for arthritis and skin disorders. Investor pressure is rising on Merck as Keytruda nears patent ...

Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely ...

Today, we meet Doina Ionescu, general manager of the healthcare division at Merck. Raised in Romania, the 56-year-old joined the Fortune 500 pharmaceutical giant, Merck, after being personally ...